RETRACTED: The best drug supplement for obesity treatment: a systematic review and network meta-analysis (Retracted article. See vol. 15, 2023)

被引:17
作者
Salari, Nader [1 ]
Jafari, Samira [2 ]
Darvishi, Niloofar [2 ]
Valipour, Elahe [3 ]
Mohammadi, Masoud [4 ]
Mansouri, Kamran [5 ]
Shohaimi, Shamarina [6 ]
机构
[1] Kermanshah Univ Med Sci, Sch Hlth, Dept Biostat, Kermanshah, Iran
[2] Kermanshah Univ Med Sci, Student Res Comm, Kermanshah, Iran
[3] Zimagene Med Genet Lab, Avicenna St, Hamadan, Hamadan, Iran
[4] Kermanshah Univ Med Sci, Sch Nursing & Midwifery, Dept Nursing, Kermanshah, Iran
[5] Kermanshah Univ Med Sci, Biol Res Ctr, Kermanshah, Iran
[6] Univ Putra Malaysia, Dept Biol, Fac Sci, Serdang, Selangor, Malaysia
关键词
Obesity; Treatment; Network-meta analysis; CARDIOVASCULAR-DISEASE RISK; PLACEBO-CONTROLLED TRIAL; WEIGHT-LOSS; DOUBLE-BLIND; BODY-WEIGHT; PHARMACOLOGICAL-TREATMENT; RANDOMIZED-TRIAL; ORLISTAT; LIRAGLUTIDE; OVERWEIGHT;
D O I
10.1186/s13098-021-00733-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Obesity is a complex disease with an increasing prevalence worldwide. There are different weight-management options for obesity treatment, including dietary control, exercise, surgery, and medication. Medications are always associated with different responses from different people. More safety and efficacy of drugs with fewer side effects are valuable for any clinical condition. In this systematic review and network meta-analysis, different anti-obesity drugs are compared to identify the most effective drug. Methods All relevant studies were extracted by searching national and international databases of SID, MagIran, ProQuest, PubMed, Science Direct, Scopus, Web of Science (WoS), and Google Scholar without time limit until October 2020. Finally, the meta-analysis was performed with the 11 remaining studies containing 14 different drug supplements. The standardized mean difference (SMD) was calculated at a 95% confidence interval (CI) to evaluate the effects of each treatment group compared with placebo. A random-effect model was used to evaluate the effect of individual studies on the final result. Heterogeneity and incompatibility of the network were assessed by Cochran's Q and Higgins I-2, and the Net Heat chart, respectively. Data analysis was performed using R software. Results Our results showed that there were significant mean effects in people intervened with Phentermine 15.0 mg + Topiramate 92.0 mg, Phentermine 7.5 mg + Topiramate 46.0 mg, Pramlintide, Naltrexone + Bupropion 32, and Liraglutide, with SMD effects size = - 9.1, - 7.4, - 6.5, - 5.9, - 5.35, respectively. Conclusion This study was performed to compare the effect of different drugs used for weight loss in obese patients. The most effective drugs for weight loss were phentermine and topiramate, pramlintide, naltrexone, bupropion, and liraglutide compared to placebo treatment, respectively. This study provides new insights into anti-obesity drugs and hopes to shed new light on future research to manage and treat obesity.
引用
收藏
页数:12
相关论文
共 61 条
[1]   A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II) [J].
Apovian, Caroline M. ;
Aronne, Louis ;
Rubino, Domenica ;
Still, Christopher ;
Wyatt, Holly ;
Burns, Colleen ;
Kim, Dennis ;
Dunayevich, Eduardo .
OBESITY, 2013, 21 (05) :935-943
[2]   Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes [J].
Ariel, D. ;
Kim, S. H. ;
Abbasi, F. ;
Lamendola, C. A. ;
Liu, A. ;
Reaven, G. M. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2014, 24 (12) :1317-1322
[3]   Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial [J].
Aronne, Louis J. ;
Halseth, Amy E. ;
Burns, Colleen M. ;
Miller, Stephan ;
Shen, Larry Z. .
OBESITY, 2010, 18 (09) :1739-1746
[4]   Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension [J].
Bakris, G ;
Calhoun, D ;
Egan, B ;
Hellmann, C ;
Dolker, M ;
Kingma, I .
JOURNAL OF HYPERTENSION, 2002, 20 (11) :2257-2267
[5]   The effectiveness of behavioural and cognitive behavioural therapies for insomnia on depressive and fatigue symptoms: A systematic review and network meta-analysis [J].
Ballesio, Andrea ;
Aquino, Maria Raisa Jessica V. ;
Feige, Bernd ;
Johann, Anna F. ;
Kyle, Simon D. ;
Spiegelhalder, Kai ;
Lombardo, Caterina ;
Rucker, Gerta ;
Riemann, Dieter ;
Baglioni, Chiara .
SLEEP MEDICINE REVIEWS, 2018, 37 :114-129
[6]   Progress and challenges in anti-obesity pharmacotherapy [J].
Bessesen, Daniel H. ;
Van Gaal, Luc F. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (03) :237-248
[7]   Update on obesity pharmacotherapy [J].
Bray, George A. ;
Ryan, Donna H. .
YEAR IN DIABETES AND OBESITY, 2014, 1311 :1-13
[8]  
Broom I, 2002, INT J CLIN PRACT, V56, P494
[9]   Obesity Treatment Among Adolescents A Review of Current Evidence and Future Directions [J].
Cardel, Michelle I. ;
Atkinson, Mark A. ;
Taveras, Elsie M. ;
Holm, Jens-Christian ;
Kelly, Aaron S. .
JAMA PEDIATRICS, 2020, 174 (06) :609-617
[10]   Effect of orlistat on weight and body composition in obese adolescents - A randomized controlled trial [J].
Chanoine, JP ;
Hampl, S ;
Jensen, C ;
Boldrin, M ;
Hauptman, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (23) :2873-2883